Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. - Wikidata - awgldk - TriplyDB

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

http://www.wikidata.org/entity/Q42581359

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards Tumor-intrinsic oncogene pathways mediating immune avoidance Advances in immunotherapy for melanoma Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Novel immunotherapies in lymphoid malignancies Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer Adaptive Immune Resistance: How Cancer Protects from Immune Attack Universes collide: combining immunotherapy with targeted therapy for cancer Overcoming T cell exhaustion in infection and cancer The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Pathways and therapeutic targets in melanoma In-situ tumor vaccination: Bringing the fight to the tumor Trial watch: IDO inhibitors in cancer therapy Innate and adaptive immune cells in the tumor microenvironment The STING pathway and the T cell-inflamed tumor microenvironment Targeting the innate immune system as immunotherapy for acute myeloid leukemia Immune escape mechanisms as a guide for cancer immunotherapy Targeting the tumor vasculature to enhance T cell activity A biased competition theory of cytotoxic T lymphocyte interaction with tumor nodules Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Recent advances in understanding antitumor immunity DNA sensor cGAS-mediated immune recognition PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Immune checkpoint blockade: a common denominator approach to cancer therapy Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential New perspectives on type I IFNs in cancer Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients PD-1 blockade induces responses by inhibiting adaptive immune resistance Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

P2860

Q21131200-5F4FBDD6-0564-4ED7-881B-6A7BE3E442E4 Q26744395-5EDE5141-32B1-49F0-8850-6C447DC7C383 Q26747707-55653CA9-F0BF-4A72-8A4A-37AA39FA797C Q26768558-C338B9DE-57E6-4300-9246-1E5C6606C474 Q26769728-78CCBF68-3E66-4D68-BCBB-E4A65A210DA6 Q26770306-0FCF1BB9-089C-4716-B943-9B3DBE4CC30C Q26774312-6BBBCA1B-3F9A-4CF8-9B6E-93D3C58D4555 Q26777394-D823B931-806B-41D6-9B3A-699884549431 Q26778793-BE4D9D4F-B8B2-46BD-B7A6-76AA42177E3F Q26796305-6F61DB5E-B84C-4EF5-8D9C-A124F5E9DEF3 Q26796309-70FF9A25-655D-4790-9EBB-C296AD6EC119 Q26798047-CF519D64-14DD-4A81-8F16-2BCBA7E7E22F Q26798448-218432D1-BAE3-4332-9B49-BB00B737B2B7 Q26825316-C8BF83AA-7847-4CF4-96D2-AEE49A11AA81 Q26829885-EE1042D4-8D28-48CF-BCC4-B49B97C3545D Q26851545-EEDE13E5-2CCE-4876-AE38-A81BB1D1E838 Q26852704-87F03C31-E1D9-47F2-80AA-ABB4F1858C6D Q26865736-E15E2C43-591E-46CD-B665-107C7ED81CC9 Q26991976-CA3031D5-BE57-4F54-80A0-F923859EC143 Q27006866-DE42BE39-EAB0-4421-B5A9-61379DB355E3 Q27008342-40327FE2-9C53-4CF7-9623-B97384C9AE10 Q27008371-BF617734-C521-4FE7-9D85-A2029FA2060C Q27015876-04D570C1-2503-4CA7-9D2D-11EE7E67088F Q27024502-DF54C732-F33E-4252-AFF5-3491C538018A Q27026329-7FA2EC4E-731B-4673-B175-501D5972B85C Q27311561-B1451A8C-6480-4045-B54C-5441D3FC5C4E Q27346770-0795940D-EDCC-41E7-812D-F917D8A8FC25 Q27853353-A96C94CF-D4B6-426B-A6EB-9E47C1B939AC Q28067217-61FD4F37-E450-4F06-A7AE-1CC2FD106FAF Q28073115-5C99E313-1050-4204-B9BE-DA9C239C5E34 Q28075712-DEB71E5E-2A45-4B14-A785-2E0791C62D64 Q28075719-F9C7CAC7-C396-4A91-A453-0685F719C34A Q28076760-EEC33B5F-360B-4916-A1D4-4A5AD37073D7 Q28078539-1DEFDB75-EA10-42E9-B4EE-8F833A9F1EA2 Q28083981-48FE8C1C-207B-4C2B-9961-59B3EF693CAD Q28084942-123B60FA-BFAA-42FD-A797-EC3F6E44E1EF Q28256099-46D87415-223D-4FF5-AF4C-7248F323C01C Q29617771-4CA9857D-AE66-4493-9463-F2B6F7A74A04 Q29620856-8C99CCA6-0DC8-416D-B68D-EA8B0A5E1923 Q30276126-BF66B1F9-6C16-48CA-9352-43D3FEA81B40

P2860

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

http://www.wikidata.org/entity/Q42581359

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@en

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@nl

type

label

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@en

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@nl

prefLabel

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@en

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@nl

P1433

Q42581359-F6C38E1F-4F34-4D5B-BD26-50964152ACCB

P1476

Q42581359-CD34BCDB-B4D4-4F24-9D2F-11367864553E

P2093

Q42581359-0BF4CC5A-9937-4069-8793-08A2B719BECD

Q42581359-7DDDBB17-8A33-4ECF-8408-3F69CA6F8E4A

Q42581359-8FB9D70B-2D7B-4EFA-A801-5B7E12B72CA9

Q42581359-8FDCE310-4C8D-4F85-918F-DFBBF809BCDE

Q42581359-B213E991-5F19-4129-BFFB-371D0DD56DF2

Q42581359-BD7BD54E-F225-4C3D-9EFF-6247D174CFF1

P2860

Q42581359-01E69F4A-A6B6-4DBE-AE11-6013D3338455

Q42581359-07F2B86A-6866-42E4-880D-8CEE9FD4FC56

Q42581359-0C83F462-0961-4763-B5FB-0084F365C3E7

Q42581359-1866A403-2AB8-492E-A8AF-708DAFF16905

Q42581359-2474D7A0-7A8F-45B4-A43F-917186785AF7

Q42581359-2EB498D9-796F-4F1A-94A7-E0EA33D0B1C9

Q42581359-327B3320-2000-4F77-8CE8-988041824C7F

Q42581359-42807958-CAF5-48BE-AE63-717646485329

Q42581359-4564383A-A9F5-46AE-9ACB-9CE251379AA9

Q42581359-4D5F8144-591F-4D2D-B4C6-768A36F5D830

P304

Q42581359-D81F4530-C304-4985-A877-B90B8FEE5A64

P31

Q42581359-A9EFCD36-67F1-4F3C-8CA8-B84F5DB973E6

P356

Q42581359-2C6BD0B6-2AA3-40D5-A744-040CFF3C2AA1

P407

Q42581359-46D60045-6F65-4395-8784-0D497FFBD8DD

P433

Q42581359-3219CFFF-3E37-4BE1-B520-DF2E484A7341

P478

Q42581359-ED27CB74-C862-4039-9C0A-9725AF0C7138

P50

Q42581359-BE9AE882-9A30-4DC2-B0A3-088B0E4E4D80

P577

Q42581359-99627FF3-26E9-454E-BF9D-A623EEEC7E8A

P698

Q42581359-B23460CB-0BD9-4F70-AE30-52125F9179B0

P932

Q42581359-6EE88933-D980-4509-80C7-4834A9E48755

P356

SCITRANSLMED.3006504

P1433

Science Translational Medicine

P1476

Up-regulation of PD-L1, IDO, a ...... t is driven by CD8(+) T cells.

@en

P2093

Jason Williams

http://www.w3.org/2001/XMLSchema#string

Stefani Spranger

http://www.w3.org/2001/XMLSchema#string

Thanh T Ha

http://www.w3.org/2001/XMLSchema#string

Thomas F Gajewski

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Zha

http://www.w3.org/2001/XMLSchema#string

Yuru Meng

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of allogeneic fetal rejection by tryptophan catabolism

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor

P304

200ra116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3006504

http://www.w3.org/2001/XMLSchema#string

P407

P433

200

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Robbert Spaapen

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23986400

http://www.w3.org/2001/XMLSchema#string

P932

4136707

http://www.w3.org/2001/XMLSchema#string